Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Limitations of bystander killing in Th1/M1 immune responses against a secreted tumor antigen.

Tveita AA, Haabeth OA, Bogen B.

Oncoimmunology. 2014 Dec 13;3(9):e954953. eCollection 2014 Oct.

2.

Indirect CD4+ T-cell-mediated elimination of MHC II(NEG) tumor cells is spatially restricted and fails to prevent escape of antigen-negative cells.

Tveita AA, Schjesvold FH, Sundnes O, Haabeth OA, Haraldsen G, Bogen B.

Eur J Immunol. 2014 Sep;44(9):2625-37. doi: 10.1002/eji.201444659. Epub 2014 Jun 20.

3.

How Do CD4(+) T Cells Detect and Eliminate Tumor Cells That Either Lack or Express MHC Class II Molecules?

Haabeth OA, Tveita AA, Fauskanger M, Schjesvold F, Lorvik KB, Hofgaard PO, Omholt H, Munthe LA, Dembic Z, Corthay A, Bogen B.

Front Immunol. 2014 Apr 15;5:174. doi: 10.3389/fimmu.2014.00174. eCollection 2014. Review.

4.

Dendritic cells purified from myeloma are primed with tumor-specific antigen (idiotype) and activate CD4+ T cells.

Dembic Z, Schenck K, Bogen B.

Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2697-702.

6.

Interferon-gamma: biologic functions and HCV therapy (type I/II) (1 of 2 parts).

Gattoni A, Parlato A, Vangieri B, Bresciani M, Derna R.

Clin Ter. 2006 Jul-Aug;157(4):377-86. Review. Retraction in: Clin Ter. 2008 May-Jun;159(3):207.

PMID:
17051976
7.

Tumor Killing by CD4+ T Cells Is Mediated via Induction of Inducible Nitric Oxide Synthase-Dependent Macrophage Cytotoxicity.

Fauskanger M, Haabeth OAW, Skjeldal FM, Bogen B, Tveita AA.

Front Immunol. 2018 Jul 23;9:1684. doi: 10.3389/fimmu.2018.01684. eCollection 2018.

9.

Tumors Escape CD4+ T-cell-Mediated Immunosurveillance by Impairing the Ability of Infiltrating Macrophages to Indirectly Present Tumor Antigens.

Tveita AA, Schjesvold F, Haabeth OA, Fauskanger M, Bogen B.

Cancer Res. 2015 Aug 15;75(16):3268-78. doi: 10.1158/0008-5472.CAN-14-3640. Epub 2015 Jun 2.

12.

Bystander T cells in human immune responses to dengue antigens.

Suwannasaen D, Romphruk A, Leelayuwat C, Lertmemongkolchai G.

BMC Immunol. 2010 Sep 20;11:47. doi: 10.1186/1471-2172-11-47.

13.

Secretion of tumor-specific antigen by myeloma cells is required for cancer immunosurveillance by CD4+ T cells.

Corthay A, Lundin KU, Lorvik KB, Hofgaard PO, Bogen B.

Cancer Res. 2009 Jul 15;69(14):5901-7. doi: 10.1158/0008-5472.CAN-08-4816. Epub 2009 Jun 30.

14.

Control of in vivo collateral damage generated by T cell immunity.

Thangavelu G, Gill RG, Boon L, Ellestad KK, Anderson CC.

J Immunol. 2013 Aug 15;191(4):1686-91. doi: 10.4049/jimmunol.1203240. Epub 2013 Jul 12.

15.
16.

Clinically feasible approaches to potentiating cancer cell-based immunotherapies.

Seledtsov VI, Goncharov AG, Seledtsova GV.

Hum Vaccin Immunother. 2015;11(4):851-69. doi: 10.1080/21645515.2015.1009814. Review.

18.

Analysis of CD4+ T cells that provide contact-dependent bystander help to B cells.

Croft M, Swain SL.

J Immunol. 1992 Nov 15;149(10):3157-65.

PMID:
1358966
19.

Cognate Interaction With CD4+ T Cells Instructs Tumor-Associated Macrophages to Acquire M1-Like Phenotype.

Eisel D, Das K, Dickes E, König R, Osen W, Eichmüller SB.

Front Immunol. 2019 Feb 22;10:219. doi: 10.3389/fimmu.2019.00219. eCollection 2019.

20.

CD4+ Th-APC with acquired peptide/MHC class I and II complexes stimulate type 1 helper CD4+ and central memory CD8+ T cell responses.

Umeshappa CS, Huang H, Xie Y, Wei Y, Mulligan SJ, Deng Y, Xiang J.

J Immunol. 2009 Jan 1;182(1):193-206.

Supplemental Content

Support Center